|
Information by division | ||||||||||
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
| ||||
|
|
Merck Serono |
Consumer Health |
Performance Materials | |||||||
|
€ million |
2012 |
2011 |
2012 |
2011 |
2012 |
2011 | ||||
| ||||||||||
|
Sales |
5,995.8 |
5,564.4 |
472.6 |
494.2 |
1,674.2 |
1,464.7 | ||||
|
Royalty, license and commission income |
409.4 |
355.6 |
2.6 |
2.0 |
1.4 |
2.7 | ||||
|
Total revenues |
6,405.2 |
5,920.0 |
475.2 |
496.2 |
1,675.6 |
1,467.4 | ||||
|
Gross margin |
5,212.1 |
4,891.71 |
316.7 |
339.01 |
959.1 |
875.31 | ||||
|
Marketing and selling expenses |
–1,370.8 |
–1,412.01 |
–218.5 |
–232.81 |
–142.8 |
–132.41 | ||||
|
Royalty, license and commission expenses |
–561.6 |
–478.5 |
–1.0 |
–3.7 |
–1.5 |
–2.3 | ||||
|
Administration expenses |
–250.2 |
–253.41 |
–23.1 |
–23.51 |
–35.2 |
–33.11 | ||||
|
Other operating expenses and income |
–674.9 |
–382.01 |
–46.2 |
–5.1 |
–39.2 |
127.41 | ||||
|
Research and development |
–1,187.3 |
–1,224.51 |
–19.4 |
–22.81 |
–137.4 |
–132.81 | ||||
|
Operating result (EBIT) |
508.3 |
342.21 |
4.3 |
46.91 |
598.5 |
691.01 | ||||
|
Depreciation and amortization |
881.1 |
840.8 |
11.5 |
11.3 |
114.1 |
102.5 | ||||
|
Impairment losses |
51.2 |
344.4 |
10.7 |
0.3 |
12.1 |
9.5 | ||||
|
Other |
– |
–0.5 |
– |
– |
–1.3 |
–1.9 | ||||
|
EBITDA |
1,440.6 |
1,526.91 |
26.5 |
58.51 |
723.4 |
801.11 | ||||
|
One-time items |
344.7 |
42.1 |
37.0 |
– |
7.3 |
–118.4 | ||||
|
EBITDA pre one-time items (Segment result) |
1,785.3 |
1,569.0 |
63.5 |
58.5 |
730.7 |
682.7 | ||||
|
EBITDA margin pre one-time items (in % of sales) |
29.8 |
28.2 |
13.4 |
11.8 |
43.6 |
46.6 | ||||
|
Net operating assets |
8,020.6 |
9,207.2 |
283.8 |
321.1 |
1,187.7 |
1,331.0 | ||||
|
Segment liabilities |
–1,349.8 |
–1,163.6 |
–76.5 |
–80.7 |
–147.1 |
–131.7 | ||||
|
Investments in property, plant and equipment2 |
146.9 |
197.0 |
4.0 |
5.2 |
55.7 |
64.1 | ||||
|
Investments in intangible assets2 |
88.7 |
53.0 |
0.4 |
6.2 |
28.6 |
2.7 | ||||
|
Net cash flows from operating activities |
2,216.3 |
1,386.91 |
72.3 |
49.41 |
875.4 |
573.81 | ||||
|
Net cash flows from investing activities |
–197.5 |
101.3 |
–2.3 |
–8.8 |
–70.8 |
128.6 | ||||
|
Free cash flow |
2,018.8 |
1,488.21 |
70.0 |
40.61 |
804.6 |
702.41 | ||||
|
Business free cash flow |
1,840.9 |
1,440.4 |
85.5 |
48.2 |
786.9 |
572.3 | ||||
|
Free cash flow margin (in % of sales) |
33.7 |
26.7 |
14.8 |
8.2 |
48.1 |
48.0 | ||||
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
| ||||
|
|
Merck Millipore |
Corporate and Other |
Group | |||||||
|
€ million |
2012 |
2011 |
2012 |
2011 |
2012 |
2011 | ||||
|
Sales |
2,598.2 |
2,382.6 |
– |
– |
10,740.8 |
9,905.9 | ||||
|
Royalty, license and commission income |
18.7 |
10.2 |
– |
– |
432.1 |
370.5 | ||||
|
Total revenues |
2,616.9 |
2,392.8 |
– |
– |
11,172.9 |
10,276.4 | ||||
|
Gross margin |
1,531.1 |
1,389.61 |
–3.8 |
–4.81 |
8,015.2 |
7,490.81 | ||||
|
Marketing and selling expenses |
–675.7 |
–606.01 |
–3.0 |
–2.51 |
–2,410.8 |
–2,385.71 | ||||
|
Royalty, license and commission expenses |
–15.7 |
–16.0 |
– |
– |
–579.8 |
–500.5 | ||||
|
Administration expenses |
–113.5 |
–104.11 |
–130.2 |
–121.51 |
–552.2 |
–535.61 | ||||
|
Other operating expenses and income |
–122.9 |
–103.01 |
–243.3 |
–54.51 |
–1,126.5 |
–417.21 | ||||
|
Research and development |
–166.1 |
–133.41 |
–1.1 |
–0.51 |
–1,511.3 |
–1,514.01 | ||||
|
Operating result (EBIT) |
233.2 |
235.41 |
–380.7 |
–183.41 |
963.6 |
1,132.11 | ||||
|
Depreciation and amortization |
305.0 |
283.7 |
7.6 |
5.4 |
1,319.3 |
1,243.7 | ||||
|
Impairment losses |
4.2 |
1.8 |
0.5 |
– |
78.7 |
356.0 | ||||
|
Other |
– |
1.5 |
–0.1 |
– |
–1.4 |
–0.9 | ||||
|
EBITDA |
542.4 |
522.41 |
–372.7 |
–178.01 |
2,360.2 |
2,730.91 | ||||
|
One-time items |
53.5 |
38.7 |
162.2 |
30.5 |
604.7 |
–7.1 | ||||
|
EBITDA pre one-time items (Segment result) |
595.9 |
561.1 |
–210.5 |
–147.5 |
2,964.9 |
2,723.8 | ||||
|
EBITDA margin pre one-time items (in % of sales) |
22.9 |
23.6 |
– |
– |
27.6 |
27.5 | ||||
|
Net operating assets |
6,328.9 |
6,608.6 |
25.1 |
–1.3 |
15,846.1 |
17,466.6 | ||||
|
Segment liabilities |
–383.1 |
–335.4 |
–33.7 |
–22.9 |
–1,990.2 |
–1,734.3 | ||||
|
Investments in property, plant and equipment2 |
113.2 |
99.7 |
9.3 |
0.3 |
329.1 |
366.3 | ||||
|
Investments in intangible assets2 |
10.0 |
12.0 |
16.5 |
5.8 |
144.2 |
79.7 | ||||
|
Net cash flows from operating activities |
639.7 |
413.41 |
–1,331.5 |
–1,152.31 |
2,472.2 |
1,271.2 | ||||
|
Net cash flows from investing activities |
–137.4 |
–263.3 |
–749.9 |
–853.8 |
–1,157.9 |
–896.0 | ||||
|
Free cash flow |
502.2 |
150.01 |
–1,355.7 |
–944.81 |
2,039.9 |
1,436.4 | ||||
|
Business free cash flow |
492.8 |
352.3 |
–236.8 |
–151.3 |
2,969.3 |
2,261.9 | ||||
|
Free cash flow margin (in % of sales) |
19.3 |
6.3 |
– |
– |
19.0 |
14.5 | ||||